First Eagle Investment Management LLC Boosts Stake in DENTSPLY SIRONA Inc. $XRAY

First Eagle Investment Management LLC raised its position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 3.2% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 14,640,555 shares of the medical instruments supplier’s stock after purchasing an additional 458,744 shares during the period. First Eagle Investment Management LLC owned approximately 0.07% of DENTSPLY SIRONA worth $167,342,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Arizona State Retirement System lifted its position in shares of DENTSPLY SIRONA by 1.4% during the third quarter. Arizona State Retirement System now owns 58,952 shares of the medical instruments supplier’s stock worth $748,000 after purchasing an additional 807 shares during the last quarter. Empowered Funds LLC lifted its position in shares of DENTSPLY SIRONA by 8.8% during the first quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock worth $244,000 after purchasing an additional 1,320 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of DENTSPLY SIRONA during the first quarter worth about $26,000. Brevan Howard Capital Management LP lifted its position in shares of DENTSPLY SIRONA by 9.9% during the second quarter. Brevan Howard Capital Management LP now owns 20,002 shares of the medical instruments supplier’s stock worth $318,000 after purchasing an additional 1,800 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its position in shares of DENTSPLY SIRONA by 119.1% during the fourth quarter. Farther Finance Advisors LLC now owns 3,773 shares of the medical instruments supplier’s stock worth $43,000 after purchasing an additional 2,051 shares during the last quarter. 95.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on XRAY shares. UBS Group reduced their price target on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Thursday. Mizuho dropped their price objective on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Robert W. Baird increased their price objective on shares of DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a research note on Friday, February 27th. Citigroup started coverage on shares of DENTSPLY SIRONA in a research note on Wednesday, April 15th. They set a “sell” rating and a $10.00 price objective on the stock. Finally, Zacks Research upgraded shares of DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research note on Monday, March 2nd. Three analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $13.82.

Insider Buying and Selling

In other DENTSPLY SIRONA news, Director Gregory T. Lucier bought 15,000 shares of DENTSPLY SIRONA stock in a transaction that occurred on Monday, March 9th. The stock was purchased at an average cost of $12.45 per share, for a total transaction of $186,750.00. Following the completion of the acquisition, the director owned 65,000 shares of the company’s stock, valued at approximately $809,250. This represents a 30.00% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James D. Forbes acquired 5,000 shares of the firm’s stock in a transaction that occurred on Monday, March 9th. The stock was purchased at an average cost of $12.48 per share, with a total value of $62,400.00. Following the purchase, the director directly owned 10,000 shares in the company, valued at approximately $124,800. This trade represents a 100.00% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 70,000 shares of company stock valued at $956,437 over the last 90 days. 0.52% of the stock is currently owned by insiders.

DENTSPLY SIRONA Price Performance

Shares of NASDAQ:XRAY opened at $10.91 on Tuesday. The firm’s 50 day moving average is $11.99 and its two-hundred day moving average is $11.97. DENTSPLY SIRONA Inc. has a 52 week low of $9.85 and a 52 week high of $17.18. The firm has a market capitalization of $2.19 billion, a P/E ratio of -3.46, a PEG ratio of 1.31 and a beta of 0.93. The company has a current ratio of 1.53, a quick ratio of 0.98 and a debt-to-equity ratio of 1.52.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.01). The firm had revenue of $880.00 million during the quarter, compared to analyst estimates of $841.80 million. DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. DENTSPLY SIRONA’s revenue for the quarter was up .1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.43 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Analysts anticipate that DENTSPLY SIRONA Inc. will post 1.42 earnings per share for the current year.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.